Patent intelligence · US
US 10052363
Mesenchymal stem cells for the treatment of CNS diseases
Mesenchymal stem cells for the treatment of CNS diseases
Patent details — US 10052363
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 21, 2018
- Expiration
- Aug 16, 2038
- Applicant
- BRAINSTORM CELL THERAPEUTICS LTD.
- Claims
- 7
- CPC classes
- A61K, A61K35/12, A61K35/28, A61K38/185
Quick answer
US 10052363 (Mesenchymal stem cells for the treatment of CNS diseases) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Aug 21, 2018. Expires Aug 16, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRAINSTORM CELL THERAPEUTICS LTD.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K35/12, A61K35/28, A61K38/185, A61P, A61P25/02
More from BRAINSTORM CELL THERAPEUTICS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12233092
MSC-NTF specific exosomes and use thereof
granted -
US 11185572
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 10564149
Populations of mesenchymal stem cells that secrete neurotrophic factors
granted -
US 10046010
Methods of generating mesenchymal stem cells which secrete neurotrophic factors
granted -
US 9474787
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 8900574
Mesenchymal stem cells for the treatment of CNS diseases
granted -
US 8663987
Mesenchymal stem cells for the treatment of CNS diseases
granted
Frequently asked questions
What is US patent 10052363?
US 10052363 (Mesenchymal stem cells for the treatment of CNS diseases) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Aug 21, 2018. Expires Aug 16, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10052363?
BRAINSTORM CELL THERAPEUTICS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 10052363 expire?
Our index shows an expiration date of Aug 16, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.